Isoniazid treatment of children: Can genetics help guide treatment?

Archives of Disease in Childhood

Volumn 90, Issue 6, 2005, Pages 551-553

  Cranswick, N ^a   Mulholland, K ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ISONIAZID;

AGE; AREA UNDER THE CURVE; BODY WEIGHT; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; GENOTYPE; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MALNUTRITION; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT;

AGE FACTORS; ANTITUBERCULAR AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; GENOTYPE; HUMANS; ISONIAZID; PHARMACOGENETICS; TUBERCULOSIS;

EID: 20344383496     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2004.063610     Document Type: Review

References (22)

1. Dye C, Scheele S, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
2. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005;90:614-18.
3. Reed MD, Besunder JB. Developmental pharmacology: ontogenic basis of drug disposition. Pediatr Clin North Am 1989;36:1053-74.
4. Palanduz A, Gultekin D, Erdem E, et al. Low level of compliance with tuberculosis treatment in children: monitoring by urine tests. Ann Trop Paediatr 2003;23:47-50.
5. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-74.
6. Basso LA, Zheng R, Musser JM, et al. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 1998;178:769-75.
7. Nolan CM, Goldberg SV, Buskin SE, et al. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-18.
8. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-30.
9. Nakajo MM, Rao M, Steiner P. Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J 1989;8:049-50.
10. Pellock JM, Howell J, Kendig EL Jr, et al. Pyridoxine deficiency in children treated with isoniazid. Chest 1985;87:658-61.
11. American Academy of Pediatrics Committee on Infectious Diseases. Chemotherapy for tuberculosis in infants and children. Pediatrics 1992;89:161-5.
12. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002;315:137-55.
13. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol 2001;15:355-9.
14. Seifart HI, Parkin DP, Botha FJ, et al. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol Drug Safety 2001;10:127-34.
15. Gerhold DL, Jensen RV, Gullans SR. Better therapeutics through microarrays. Nat Genet 2002;32(suppl):547-51.
16. West GB, Woodruff WH, Brown JH. Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. Proc Natl Acad Sci USA 2002;99(suppl 1):2473-8.
17. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000;50:125-34.
18. Anderson BJ, Holford NH, Woollard JA. Aspects of theophylline clearance in children. Anaesth Intensive Care 1997;25:497-501.
19. Boreus LO. The role of therapeutic drug monitoring in children. Clin Pharmacokinet 1989;17(suppl 1):4-12.
20. Rey E, Pons G, Cremier O, et al. Isoniazid dose adjustment in a pediatric population. Ther Drug Monit 1998;20:50-5.
21. Veenstra DL, Higashi MK, Phillips KA, et al. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm Sci 2000;2:e29.
22. Danzon P, Towse A. The economics of gene therapy and of pharmacogenetics. Value in Health 2002;5:5-13.